Omalizumab

BNF:
3.4.2
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED: TA278 for the treatment of severe persistent allergic asthma. NHS England drug. To be used in line with NHS England commissioning intentions.

RED: TA339 for previously treated chronic spontaneous urticaria (Decision date - July 2015). ICB commissioned. 

DNP: TA678 - Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (Decision date - March 2021)


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app